Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin® in 3L R and R Follicular Lymphoma ...Middle East

Webcast to be held at 08.30 CEST on Wednesday 6 July OSLO, Norway, July 5, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed and anti-CD20 refractory...

Hence then, the article about nordic nanovector to discontinue paradigme its phase 2b trial with betalutin in 3l r and r follicular lymphoma was published today ( Tuesday 05/07/2022 - 11:56 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin® in 3L R and R Follicular Lymphoma )

Also on site :

• Telford man to face trial after denying multiple child sex charges
• World Heritage Sites Hit in Airstrikes on Iran
• India eases norms for investment from China – media